Sorial MN, Huynh JP, Azzoli CG, et al. - Among patients with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC), researchers investigated how outcomes of therapy with chemotherapy and immune-checkpoint inhibitors (CICPI) is modified by prior systemic corticosteroid exposure. Researchers performed a retrospective cohort study applying electronic health records to analyze patients with mNSCLC or ES-SCLC who were given chemotherapy (CT) between April 1, 2015 and January 31, 2018 or CICPI between February 1, 2018 and August 31, 2019. They applied the inverse probability of treatment weighting (IPW) to adjust for potential confounding. The study included a total of 316 patients, with 228 CT-treated and 88 CICPI-treated patients. The findings revealed that corticosteroid use before CICPIs was not correlated with worse outcomes, implying that corticosteroids chould be used with CICPIs when indicated.